Association of Her-2 Expression and Clinicopathological Parameters in Colorectal Carcinoma in Indian Population
DOI:
https://doi.org/10.3889/oamjms.2019.008Keywords:
HER-2/neu, IHC, Colorectal Cancer (CRC), Prognostic, BiomarkerAbstract
BACKGROUND: Human epidermal growth factor receptor 2 (HER-2) is an oncogenic gene and a well-established therapeutic target in several cancers including breast and ovary.
AIM: The present study aimed to compare HER-2 expression status with histological grades as well as Clinicopathological parameters including age, bleeding per rectum, pain/burning sensation in defecation and exercise.
METHODS: Her-2 status was assessed by immunohistochemistry (IHC).
RESULTS: Results of the study shows that 40.96% patients were Her-2 positive for expression and a statistically significant difference (p-value = 0.004) was observed in histological grades where most of the cases were of grade II. We also observed a significant difference in histological grades with gender (p-value = 0.04), as well as in both the age groups ≤ 55 years and > 55 years (p-value = < 0.0001). Patients with the bleeding rectum and pain/burning sensation in defecation had grade II/III tumours (93.4%, 88.7%) respectively. A significant association was observed between bleeding per rectum and pain/burning sensation in defecation. About 95% of patients with pain/burning sensation in defecation had bleeding per rectum.
CONCLUSION: To conclude, Her-2 can be a potential prognostic marker in CRC. The role of age, tumour grade and bleeding per rectum/burning sensation in defecation are of significant worth. Thus, CRC cases of high grades can be screened for HER-2/neu positivity so that they can be subjected to mAb-based individualised therapy.
Downloads
Metrics
Plum Analytics Artifact Widget Block
References
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. GLOBOCAN 2012 v1. 1, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11. International Agency for Research on Cancer. World Health Organization, 2014. PMCid:PMC4314462
Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5:341-54. https://doi.org/10.1038/nrc1609 PMid:15864276 DOI: https://doi.org/10.1038/nrc1609
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987; 235(4785):177-82. https://doi.org/10.1126/science.3798106 PMid:3798106 DOI: https://doi.org/10.1126/science.3798106
Sharpe S, Barber KR, Grant CW. Evidence of a tendency to self-association of the transmembrane domain of ErbB-2 in fluid phospholipid bilayers. Biochemistry. 2002; 41(7):2341-52. https://doi.org/10.1021/bi011340f PMid:11841227 DOI: https://doi.org/10.1021/bi011340f
Tan M, Yao J, Yu D. Overexpression of the c-erbB-2 gene enhanced intrinsic metastasis potential in human breast cancer cells without increasing their transformation abilities. Cancer research. 1997; 57(6):1199-205. PMid:9067293
Guy CT, Webster MA, Schaller M, Parsons TJ, Cardiff RD, Muller WJ. Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proceedings of the National Academy of Sciences. 1992; 89(22):10578-82. https://doi.org/10.1073/pnas.89.22.10578 DOI: https://doi.org/10.1073/pnas.89.22.10578
Doherty JK, Bond C, Jardim A, Adelman JP, Clinton GM. The HER-2/neu receptor tyrosine kinase gene encodes a secreted autoinhibitor. Proceedings of the National Academy of Sciences. 1999; 96(19):10869-74. https://doi.org/10.1073/pnas.96.19.10869 DOI: https://doi.org/10.1073/pnas.96.19.10869
Guesdon JL, Ternynck TH, Avrameas ST. The use of avidin-biotin interaction in immunoenzymatic techniques. Journal of Histochemistry & Cytochemistry. 1979; 27(8):1131-9. https://doi.org/10.1177/27.8.90074 PMid:90074 DOI: https://doi.org/10.1177/27.8.90074
Shi SR, Cote RJ, Taylor CR. Antigen retrieval techniques: current perspectives. Journal of Histochemistry & Cytochemistry. 2001; 49(8):931-7. https://doi.org/10.1177/002215540104900801 PMid:11457921 DOI: https://doi.org/10.1177/002215540104900801
Ries LA, Harkins D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, Clegg LX, Eisner MP, Horner MJ, Howlader N, Hayat M. SEER cancer statistics review, 1975-2003.
Ung L, Chua TC, Merrett ND. Targeting HER2 amplifications in gastric cancer. Gastrointestinal Cancer: Targets and Therapy. 2014; 4:11-22. DOI: https://doi.org/10.2147/GICTT.S57199
Blok EJ, Kuppen PJ, van Leeuwen JE, Sier CF. Cytoplasmic overexpression of HER2: a key factor in colorectal cancer. Clin Med Insights Oncol. 2013; 7:41. https://doi.org/10.4137/CMO.S10811 PMid:23471238 PMCid:PMC3583442 DOI: https://doi.org/10.4137/CMO.S10811
Dittmar T, Husemann A, Schewe Y, Nofer JR, Niggemann B, Zanker KS, et al. Induction of cancer cell migration by epidermal growth factor is initiated by specific phosphorylation of tyrosine 1248 of c-erbB-2 receptor via EGFR. FASEB J. 2002; 16(13):1823–5. https://doi.org/10.1096/fj.02-0096fje PMid:12354693 DOI: https://doi.org/10.1096/fj.02-0096fje
Kaptain S, Tan LK, Chen B. Her-2/neu and breast cancer. Diagn Mol Pathol. 2001; 10(3):139–52. https://doi.org/10.1097/00019606-200109000-00001 PMid:11552716 DOI: https://doi.org/10.1097/00019606-200109000-00001
Ross JS, McKenna BJ. The HER-2/neu oncogene in tumors of the gastrointestinal tract. Cancer Invest. 2001; 19(5):554–68. https://doi.org/10.1081/CNV-100103852 DOI: https://doi.org/10.1081/CNV-100103852
McKay JA, Loane JF, Ross VG, Ameyaw MM, Murray GI, Cassidy J, et al. c-erbB-2 is not a major factor in the development of colorectal cancer. Br J Cancer. 2002; 86(4):568–73. https://doi.org/10.1038/sj.bjc.6600127 PMid:11870539 PMCid:PMC2375271 DOI: https://doi.org/10.1038/sj.bjc.6600127
Chen J, Li Q, Wang C, Wu J, Zhao G. Prognostic significance of c-erbB-2 and vascular endothelial growth factor in colorectal liver metastases. Ann Surg Oncol. 2010; 17(6):1555–63. https://doi.org/10.1245/s10434-009-0897-3 PMid:20069460 DOI: https://doi.org/10.1245/s10434-009-0897-3
Lu Y, Jingyan G, Baorong S, Peng J, Xu Y, Cai S. Expression of EGFR, Her2 predict lymph node metastasis (LNM)-associated metastasis in colorectal cancer. Cancer Biomark. 2012; 11(5):219–26. https://doi.org/10.3233/CBM-2012-00282 PMid:23220854 DOI: https://doi.org/10.3233/CBM-2012-00282
Park DI, Kang MS, Oh SJ, Kim HJ, Cho YK, Sohn CI, et al. HER-2/neu overexpression is an independent prognostic factor in colorectal cancer. Int J Colorectal Dis. 2007; 22(5):491–7. https://doi.org/10.1007/s00384-006-0192-8 PMid:16947041 DOI: https://doi.org/10.1007/s00384-006-0192-8
van Triest B, Pinedo HM, Blaauwgeers JL, van Diest PJ, Schoenmakers PS, Voorn DA, et al. Prognostic role of thymidylate synthase, thymidine phosphorylase/platelet-derived endothelial cell growth factor, and proliferation markers in colorectal cancer. Clin Cancer Res. 2000; 6(3):1063–72. PMid:10741735
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2019 Rameez Hasan, Deepti Bhatt, Shahbaz Khan, Vasiuddin Khan, Amit Kumar Verma, Afzal Anees, Kapil Dev
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
http://creativecommons.org/licenses/by-nc/4.0
